Procurement Windfall for SIGA as US Government Places $138M Smallpox Vaccine Order

SIGA Technologies (Nasdaq: SIGA) is set to receive more than $138 million following a procurement order by the US Department of Health and Human Services for the delivery of approximately $113 million worth of oral TPOXX® treatment courses and approximately $25 million worth of IV TPOXX® treatment courses.

SIGA expects to deliver approximately $113 million of oral TPOXX under this order in 2023 and expects to start delivering IV TPOXX under this order in 2024.

Highlights

Phil Gomez, CEO of SIGA, said, “Building on the orders SIGA received for TPOXX from 13 international customers and the U.S. Department of Defense in 2022, these most recent procurement orders further highlight that many global leaders in public health recognize the importance of orthopoxvirus preparedness and the need to take action to keep people safe.”

SIGA stated the global demand for oral TPOXX is driving substantial and increasingly diversified global revenue opportunities at SIGA.

This project has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA) and Strategic National Stockpile.

Smallpox is a contagious, disfiguring and often deadly disease that was eradicated worldwide by 1980. A vaccine can prevent smallpox but is currently not recommended for routine vaccination.

About SIGA Technologies

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the US maintains a supply of TPOXX under Project BioShield. In September 2018, SIGA signed a contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, for additional procurement and development related to both oral and intravenous formulations of TPOXX. For more information about SIGA, please visit www.siga.com.

Share This Article

 

About the Author

Procurement Windfall for SIGA as US Government Places $138M Smallpox Vaccine Order

Editor Prism MarketView